Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials (Q41419107)

30 September 2017

1 reference

title

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials (English)

1 reference

30 September 2017

1 reference

hepatocellular carcinoma

1 reference

R G Simonetti

1 reference

30 September 2017

A Liberati

series ordinal

1 reference

30 September 2017

C Angiolini

series ordinal

1 reference

30 September 2017

L Pagliaro

series ordinal

1 reference

30 September 2017

publication date

1 February 1997

1 reference

30 September 2017

1 reference

30 September 2017

1 reference

30 September 2017

1 reference

30 September 2017

page(s)

117-136

1 reference

Primary hepatocellular carcinoma—etiology, pathogenesis, and prevention

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Hepatocellular carcinoma in chinese males and females. Possible causes for the male predominance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Hepatocellular carcinoma. A worldwide problem and the major risk factors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Hepatocellular carcinoma: Recent progress

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Clinical trials in primary hepatocellular carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Interferon therapy of chronic hepatitis B virus infection in Chinese

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Overview of randomised trials of diuretics in pregnancy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Meta-analysis in clinical research

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Chemohormonal therapy of unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: An RTOG study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008285123736

7 January 2021

Identifiers

DOI

10.1023/A:1008285123736

1 reference

30 September 2017

1 reference